FDA clears Armata Pharma's application for its treatment for prosthetic joint infection

Aug. 01, 2022 9:48 AM ETArmata Pharmaceuticals, Inc. (ARMP)By: Anuron Mitra, SA News Editor

FDA headquarters in Washington DC.


  • Armata Pharmaceuticals (NYSE:ARMP) on Monday said the U.S. Food and Drug Administration (FDA) had cleared the company's investigational new drug (IND) application for its AP-SA02 treatment for prosthetic joint infection.
  • Prosthetic joint infection is a serious complication that can occur in patients who have received prosthetic joints.
  • The IND clearance paves the way for the company to start its phase 1b/2a trial that will evaluate the safety, tolerability, and pharmacokinetics of AP-SA02 as an adjunct to standard of care antibiotics in subjects with prosthetic joint infection.
  • Armata is a clinical-stage biotech that develops biologics for the treatment of antibiotic-resistant bacteria. Its AP-SA02 product candidate comprises of natural lytic phages that target the bacterial pathogen Staphylococcus aureus.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.